Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177232 | 1.00 | ALDH1A1 (0.51) | ALDH1A1NOD1SLC6A5GNPATABCC4 | |
| SCHEMBL452804 | 0.88 | ABCC4 (0.56) | ALDH1A1NOD1SLC6A5GNPATABCC4 | |
| SCHEMBL452803 | 0.88 | ABCC4 (0.56) | ALDH1A1NOD1SLC6A5GNPATABCC4 | |
| SCHEMBL2894648 | 0.88 | SLC6A5 (0.59) | ALDH1A1NOD1SLC6A5GNPATABCC4 | |
| SCHEMBL2897531 | 0.88 | SLC6A5 (0.59) | ALDH1A1NOD1SLC6A5GNPATABCC4 | |
| SCHEMBL7045660 | 0.88 | NOD1 (0.63) | NOD1SLC6A5GNPATKMT2A | |
| SCHEMBL7047220 | 0.88 | NOD1 (0.63) | NOD1SLC6A5GNPATKMT2A | |
| SCHEMBL7046045 | 0.86 | NOD1 (0.60) | NOD1SLC6A5GNPATKMT2A | |
| SCHEMBL24805419 | 0.83 | NOD1 (0.58) | NOD1SLC6A5GNPATEPHX2 | |
| SCHEMBL7602122 | 0.83 | NOD1 (0.58) | NOD1SLC6A5GNPATEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0815833-B1 | Malodour preventing agents | GIVAUDAN SA (CH) | 2003-04-09 | — | — | EP | claimed |
| US-7388105-B2 | Compounds and use to reduce the formation of malodour | GIVAUDAN S.A. (CH) | 2008-06-17 | — | — | US | disclosed |
| US-7388105-B2 | Compounds and use to reduce the formation of malodour | GIVAUDAN S.A. (CH) | 2008-06-17 | — | — | US | disclosed |
| US-20070092476-A1 | Compounds and use to reduce the formation of malodour | GIVAUDAN S.A. (CH) | 2007-04-26 | — | — | US | disclosed |
| US-20070092476-A1 | Compounds and use to reduce the formation of malodour | GIVAUDAN S.A. (CH) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070092476-A1 | Compounds and use to reduce the formation of malodour | LPO, DDO, DDT | ALDH1A1 737/4885NOD1 4606/4885SLC6A5 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.